

Revision date: 16-Dec-2009 Version: 3.0 Page 1 of 8

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Pfizer Ltd

Emergency telephone number:

ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Nitroglycerin Tablets (0.4, and 0.6 mg)

Trade Name: NITROSTAT; VERNIES

Chemical Family: Mixture

Intended Use: Pharmaceutical product for the treatment of angina pectoris

2. HAZARDS IDENTIFICATION

Appearance: Round, white tablet

Signal Word: DANGER

Statement of Hazard: Toxic if swallowed.

Toxic if inhaled.

Toxic in contact with skin.

Additional Hazard Information:

Short Term: May be absorbed through the skin and cause systemic effects. Chest pain, acute myocardial

infarction, and sudden death have occurred during temporary withdrawal of organic nitrates

from industrial workers exposed for long periods of time.

Known Clinical Effects: Headache, which may be severe and persistent, may occur immediately after use. Vertigo,

dizziness, weakness, palpitation, and other manifestations of postural hypotension may develop occasionally. Flushing, drug rash, and exfoliative dermatitis have been reported in

patients receiving nitrate therapy.

EU Indication of danger: Toxic

EU Hazard Symbols:



EU Risk Phrases:

R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed.

R33 - Danger of cumulative effects.

Australian Hazard Classification

(NOHSC):

Hazardous Substance. Non-Dangerous Goods.

DD007

Material Name: Nitroglycerin Tablets (0.4, and 0.6 mg) Page 2 of 8

Revision date: 16-Dec-2009 Version: 3.0

2. HAZARDS IDENTIFICATION

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Nitroglycerin	55-63-0	200-240-8	E;R3 N;R51-53 R33 T+;R26/27/28	1.14 - 1.5
Glyceryl monostearate	31566-31-1	250-705-4	Not Listed	*
Calcium stearate	1592-23-0	216-472-8	Not Listed	*
Starch, pregelatinized	9005-25-8	232-679-6	Not Listed	*
Silicon dioxide, colloidal NF	7631-86-9	231-545-4	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Lactose NF, monohydrate	64044-51-5	Not listed	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention Eye Contact:

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not Ingestion:

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Remove to fresh air and keep patient at rest. Seek medical attention immediately. Inhalation:

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Symptoms and Effects of Exposure:

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

During all fire fighting activities, wear appropriate protective equipment, including self-**Fire Fighting Procedures:**

contained breathing apparatus.

Material Name: Nitroglycerin Tablets (0.4, and 0.6 mg) Page 3 of 8 Revision date: 16-Dec-2009 Version: 3.0

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken,

avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or

other equivalent controls.

Store as directed by product packaging. **Storage Conditions:**

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Nitroglycerin

0.05 ppm TWA **ACGIH Threshold Limit Value (TWA)**

ACGIH - Skin Absorption Designation Listed Australia TWA 0.05 ppm

0.46 mg/m³

Austria OEL - MAKs Listed **Belgium OEL - TWA** Listed Czech Republic OEL - TWA Listed Estonia OEL - TWA Listed

Finland OEL - TWA Listed France OEL - TWA Listed **Germany - Biological Exposure Limit:** Listed **Greece OEL - TWA** Listed Listed **Hungary OEL - TWA Ireland OEL - TWAs** Listed 0.05 ppm Japan - OELs - Ceilings

0.46 mg/m³

Lithuania OEL - TWA Listed **OSHA - Final PELs - Skin Notations:** Listed Poland OEL - TWA Listed

Listed Portugal OEL - TWA

Material Name: Nitroglycerin Tablets (0.4, and 0.6 mg) Page 4 of 8

Revision date: 16-Dec-2009 Version: 3.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Romania OEL - TWA Listed
Slovenia OEL - TWA Listed
Spain OEL - TWA Listed
Sweden OEL - TWAs Listed
UK - Biological Exposure Limit: Listed

Glyceryl monostearate

10 mg/m³ TWA **ACGIH Threshold Limit Value (TWA)** 10 mg/m³ **Australia TWA Belgium OEL - TWA** Listed Ireland OEL - TWAs Listed Lithuania OEL - TWA Listed Portugal OEL - TWA Listed Spain OEL - TWA Listed **Sweden OEL - TWAs** Listed

Calcium stearate

10 mg/m³ TWA **ACGIH Threshold Limit Value (TWA)** 10 mg/m³ **Australia TWA** Listed **Belgium OEL - TWA Ireland OEL - TWAs** Listed Listed Lithuania OEL - TWA Portugal OEL - TWA Listed Spain OEL - TWA Listed Listed **Sweden OEL - TWAs**

Starch, pregelatinized

ACGIH Threshold Limit Value (TWA) 10 mg/m³ TWA 10 mg/m³ **Australia TWA** Listed **Belgium OEL - TWA Bulgaria OEL - TWA** Listed Czech Republic OEL - TWA Listed Listed **Greece OEL - TWA Ireland OEL - TWAs** Listed 15 mg/m3 total **OSHA - Final PELS - TWAs:** 5 mg/m³

Portugal OEL - TWA Listed
Spain OEL - TWA Listed

Silicon dioxide, colloidal NF

Australia TWA 2 mg/m³
Austria OEL - MAKs Listed
Czech Republic OEL - TWA Listed
Estonia OEL - TWA Listed
Germany - TRGS 900 - TWAS 4 mg/m³
Germany (DFG) - MAK 4 mg/m³ MAK

Ireland OEL - TWAsListedLatvia OEL - TWAListed

OSHA - Final PELs - Table Z-3 Mineral D: - (80)/(% SiO2) mg/m³ TWA

TWA-20 mppcf

Slovenia OEL - TWA Listed

Material Name: Nitroglycerin Tablets (0.4, and 0.6 mg)

Revision date: 16-Dec-2009

Version: 3.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:TabletColor:WhiteMolecular Formula:MixtureMolecular Weight:Mixture

The active ingredient in this formulation is highly explosive. However, based on the amount of

active ingredient contained in this product it is not expected to pose an explosion risk.

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: Avoid direct sunlight, conditions that might generate heat, and sources of ignition.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: None known

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Glyceryl monostearate

Mouse IP LD50 200 mg/kg

Nitroglycerin

Rat Oral LD50 105 mg/kg Mouse Oral LD50 115 mg/kg Rabbit Dermal LD50 > 280 mg/kg Rat Dermal LD50 > 29 mg/kg

Rat IV LD50 23.2 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Page 6 of 8

Material Name: Nitroglycerin Tablets (0.4, and 0.6 mg)

Revision date: 16-Dec-2009 Version: 3.0

11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Nitroglycerin

Fertility and Embryonic Development Rat Oral 434 mg/kg/day NOAEL Negative Embryo / Fetal Development Rabbit Oral 240 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Nitroglycerin

Bacterial Mutagenicity (Ames) Salmonella Positive In Vivo Dominant Lethal Assay Rat Negative In Vitro Cytogenetics Rat Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Nitroglycerin

2 Year(s) Rat Oral 434 mg/kg/day LOAEL Liver, Male reproductive system

2 Year(s) Mouse Oral 1058 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Silicon dioxide, colloidal NF

IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Based on the concentration of the active ingredient in the formulation, No harmful effects to

aquatic organisms are expected.

Bioaccumulation and Toxicity: See aquatic toxicity data, below.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Nitroglycerin

Lepomis macrochirus (Bluegill Sunfish) LC50 96 Hours 1.91 mg/L

Midge LC50 48 Hours 20 mg/L

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

Nitroglycerin

RCRA - P Series Wastes Listed

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

DD007

Material Name: Nitroglycerin Tablets (0.4, and 0.6 mg)

Revision date: 16-Dec-2009

Page 7 of 8

Version: 3.0

version date. 10-Dec-2009

14. TRANSPORT INFORMATION

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Toxic

EU Risk Phrases:

R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed.

R33 - Danger of cumulative effects.

EU Safety Phrases:

S22 - Do not breathe dust.

S36 - Wear suitable protective clothing.

S45 - In case of accident or if you feel unwell seek medical advice immediately (show the label

where possible).

OSHA Label:

DANGER

Toxic if swallowed.

Toxic if inhaled.

Toxic in contact with skin.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision B



Nitroglycerin

CERCLA/SARA 313 Emission reporting 1.0% de minimis concentration

CERCLA/SARA Hazardous Substances 10 lb final RQ and their Reportable Quantities: 4.54 kg final RQ

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling
for Drugs and Poisons:

Schedule 2
Schedule 3
Schedule 4

EU EINECS/ELINCS List 200-240-8

Glyceryl monostearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Listed

Material Name: Nitroglycerin Tablets (0.4, and 0.6 mg)

Revision date: 16-Dec-2009

Page 8 of 8

Version: 3.0

15. REGULATORY INFORMATION

EU EINECS/ELINCS List 250-705-4

Calcium stearate

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedREACH - Annex IV - Exemptions from thePresent

obligations of Register:

EU EINECS/ELINCS List 216-472-8

Starch, pregelatinized

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedREACH - Annex IV - Exemptions from thePresent

obligations of Register:

EU EINECS/ELINCS List 232-679-6

Silicon dioxide, colloidal NF

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

231-545-4

Lactose NF, monohydrate

Australia (AICS): Listed

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R 3 - Extreme risk of explosion by shock, friction, fire or other sources of ignition.

R33 - Danger of cumulative effects.

R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed.

R51/53 - Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13

- Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet